Title of article :
The role of rivaroxaban in left ventricular thrombi
Author/Authors :
Abdelnaby, Mahmoud Cardiology and Angiology Unit - Department of Clinical and Experimental Internal Medicine - Medical Research Institute - University of Alexandria - Alexandria - Egypt , Almaghraby, Abdallah Department of Cardiology - Faculty of Medicine - University of Alexandria - Alexandria - Egypt , Abdelkarim, Ola Department of Cardiology - Faculty of Medicine - University of Alexandria - Alexandria - Egypt , Saleh, Yehia Department of Internal Medicine - Michigan State University - East Lansing - Michigan-United States of America , Hammad, Basma Department of Cardiology - Massachusetts General Hospital - Boston-United States of America , Badran, Haitham Department of Cardiology - Ain Shams University - Cairo - Egypt
Abstract :
Left ventricular (LV) thrombus is usually seen in patients
with significantly reduced LV systolic function especially those
surviving a large ST-elevation myocardial infarction (STEMI). It
usually occurs when the STEMI is anterior, anterolateral or anteroseptal with a large area of akinesia or dyskinesia involving
the apex. It may occur following an inferior or a posterior STEMI
with large akinetic segments in the inferior or posterior walls in
rare occasions (1).
The main risk associated with LV thrombi is distal systemic
embolization that usually occurs during the first 3 - 4 months after
infarction (2, 3).
The main clinical consequence of thromboembolism is the
occurrence of stroke, and the current guidelines do recommend the use of vitamin K antagonists (VKAs) as a preventive
measure in patients with LV thrombus
Keywords :
Left ventricular apical thrombi , Novel Oral Anticoagulants (NOACs) , Rivaroxaban , Vitamin K Antagonist (VKA) , Acute Coronary Syndromes (ACS) , Dual Antiplatelet Therapy (DAPT)
Journal title :
The Anatolian Journal of Cardiology: Andolu Kardiyoloji Dergisi
